{
  "abstract": "Background and Importance Monoclonal antibodies against CGRP (fremanezumab, galcanezumab, eptinezumab) or its receptor (erenumab) and the recently approved oral CGRP receptor antagonists (atogepant, rimegepant) are drugs indicated in migraine prophylaxis in adults. These treatments have proven effective in reducing both the frequency and severity of migraine episodes.Aim and Objectives To compare the persistence of different anti-CGRP treatments in patients with migraine.Material and Methods A retrospective, non-interventional, longitudinal study was conducted including patients with chronic or episodic migraine treated with an anti-CGRP drug at our centre. Persistence was defined as the duration of time from treatment initiation to discontinuation (last dispensing or end of follow-up in September 2025).Covariates collected from medical records were age, sex, line of therapy and medication possession ratio.Kaplan–Meier survival analysis was performed and differences were evaluated using the log-rank test. Data were analysed using SPSSv27.Results 285 patients were included (84.9% female, 15.1% male); age (mean±SD) was 49.8±11.9 years.Treatment distribution was: fremanezumab 51.2%, erenumab 19.6%, galcanezumab 8.4%, eptinezumab 14.4%, atogepant 6.0% and rimegepant 0.45%.Overall, median persistence duration was 451 days (CI 95% 311–590): females 490 days (CI 95% 345–635), males 260 days (CI 95% 159–360). According to treatment: fremanezumab 464 days (CI 95% 258–669), erenumab 246 days (CI 95% 75–417), galcanezumab 172 days (CI 95% 0–609), eptinezumab 581 days (CI 95% 458–703), atogepant 311 days (CI 95% 147–475) and rimegepant 326 days (not reached). According to treatment line: first 464 days (CI 95% 283–645), second 356 days (CI 95% 0–716), third 490 days (CI 95% 356–624), and fourth 221 days (CI 95% 94–348).There were no statistically significant differences between the groups.In the subcutaneous group (fremanezumab, erenumab, galcanezumab; n=226), 84.1% were female and 15.9% male; 64.6% received fremanezumab, 24.8% erenumab, 10.6% and galcanezumab; 75.7% were on first-line therapy, 21.7% second-line and 2.7% third-line.Significant differences were found between erenumab and fremanezumab (HR = 0.53; 95% CI 0.32–0.89; p=0.015).Conclusion and Relevance There were no statistically significant differences in persistence between anti-CGRP therapies in our study. Higher persistence rates were observed for eptinezumab and fremanezumab. Among subcutaneous agents, fremanezumab demonstrated significantly greater persistence compared with erenumab.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario De Getafe, Pharmacy Service, Madrid, Spain"
      ],
      "name": "A Maraver Villar"
    },
    {
      "affiliations": [
        "Hospital Universitario De Getafe, Pharmacy Service, Madrid, Spain"
      ],
      "name": "M Gomez Bermejo"
    },
    {
      "affiliations": [
        "Hospital Universitario De Getafe, Pharmacy Service, Madrid, Spain"
      ],
      "name": "J Sanchez-Rubio Ferrandez"
    },
    {
      "affiliations": [
        "Hospital Universitario De Getafe, Pharmacy Service, Madrid, Spain"
      ],
      "name": "A Onteniente Gonzalez"
    },
    {
      "affiliations": [
        "Hospital Universitario De Getafe, Pharmacy Service, Madrid, Spain"
      ],
      "name": "T Molina Garcia"
    }
  ],
  "title": "4CPS-304 Persistence analysis with anti-calcitonin gene-related peptide prophylactic treatments in patients with migraine",
  "uid": "6580652f-3baa-55e0-96e0-ad02667f6d02"
}